1. Home
  2. SNDX vs AAOI Comparison

SNDX vs AAOI Comparison

Compare SNDX & AAOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • AAOI
  • Stock Information
  • Founded
  • SNDX 2005
  • AAOI 1997
  • Country
  • SNDX United States
  • AAOI United States
  • Employees
  • SNDX N/A
  • AAOI N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • AAOI Semiconductors
  • Sector
  • SNDX Health Care
  • AAOI Technology
  • Exchange
  • SNDX Nasdaq
  • AAOI Nasdaq
  • Market Cap
  • SNDX 1.1B
  • AAOI 950.4M
  • IPO Year
  • SNDX 2016
  • AAOI 2013
  • Fundamental
  • Price
  • SNDX $15.71
  • AAOI $26.98
  • Analyst Decision
  • SNDX Strong Buy
  • AAOI Buy
  • Analyst Count
  • SNDX 10
  • AAOI 6
  • Target Price
  • SNDX $38.40
  • AAOI $28.40
  • AVG Volume (30 Days)
  • SNDX 2.2M
  • AAOI 5.2M
  • Earning Date
  • SNDX 11-04-2025
  • AAOI 11-06-2025
  • Dividend Yield
  • SNDX N/A
  • AAOI N/A
  • EPS Growth
  • SNDX N/A
  • AAOI N/A
  • EPS
  • SNDX N/A
  • AAOI N/A
  • Revenue
  • SNDX $77,933,000.00
  • AAOI $368,233,000.00
  • Revenue This Year
  • SNDX $585.73
  • AAOI $91.13
  • Revenue Next Year
  • SNDX $94.17
  • AAOI $55.88
  • P/E Ratio
  • SNDX N/A
  • AAOI N/A
  • Revenue Growth
  • SNDX 2126.66
  • AAOI 77.94
  • 52 Week Low
  • SNDX $8.58
  • AAOI $9.71
  • 52 Week High
  • SNDX $22.50
  • AAOI $44.50
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 58.19
  • AAOI 59.33
  • Support Level
  • SNDX $15.59
  • AAOI $22.74
  • Resistance Level
  • SNDX $16.65
  • AAOI $28.03
  • Average True Range (ATR)
  • SNDX 0.81
  • AAOI 1.93
  • MACD
  • SNDX -0.23
  • AAOI 0.40
  • Stochastic Oscillator
  • SNDX 28.68
  • AAOI 84.14

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About AAOI Applied Optoelectronics Inc.

Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.

Share on Social Networks: